Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5258-5265

  Attanasio, Roberto ^a   Baldelli, Roberto ^b   Pivonello, Rosario ^c   Grottoli, Silvia ^d   Bocca, Liliana ^e   Gasco, Valentina ^d   Giusti, Massimo ^e   Tamburrano, Guido ^b   Colao, Annamaria ^c   Cozzi, Renato ^a,f  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GROWTH HORMONE; LAN 60; SOMATOMEDIN C;

ABDOMINAL DISTENSION; ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOLLOW UP; GALLSTONE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NAUSEA; NORMAL VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATORRHEA; TACHYPHYLAXIS;

ACROMEGALY; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 10744220389     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030266     Document Type: Article

References (51)

1. Colao A, Lombardi G 1998 Growth hormone and prolactin excess. Lancet 352:1455-1461
2. Wright AD, Hill DM, Lowy C, Fraser TR 1970 Mortality in acromegaly. Q J Med 39:1-16
3. Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
4. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
5. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
6. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, for the Acromegaly Treatment Consensus Workshop Participants 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
7. Heron I, Thomas F, Dero M, Poutrain JR, Henane S, Catus F, Kuhn JM 1993 Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med 22:526-531
8. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC 1995 Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267-3272
9. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
10. Di Chiro G, Nelson KB 1962 The volume of the sella turcica. Am J Radiol 87:989-1008
11. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless W 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 3:1133-1140
12. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
13. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F 1994 Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131:20-26
14. Morange I, De Boisvilliers F, Chanson P, Lucas B, Dewailly D, Catus F, Thomas F, Jacquet P 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79: 145-151
15. Giusti M, Gussoni G, Cuttica CM, Giordano G 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab 81:2089-2097
16. Caron P, Morange-Ramos I, Cogne M, Jaquet P 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide J Clin Endocrinol Metab 82:18-22
17. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano G 1997 Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277-284
18. Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G 1999 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22:40-47
19. Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR 1999 Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 22:409-418
20. Chanson P, Leselbaum A, Blumberg J, Schaison G 2000 Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2:269-276
21. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G 2000 Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577-584
22. Cannavo S, Squatrito S, Curto L, Almoto B, Vieni A, Trimarchi F 2000 Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 32:224-229
23. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G 2000 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099-4103
24. Cannavo S, Squatrito S, Curto L, Almoto B, Trimarchi F 2001 Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618-624
25. Attanasio R, Barausse M, Cozzi R 2001 GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 24:209-216
26. Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M 1999 Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom 68:165-167
27. Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M 1999 Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 83:1506-1509
28. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G 1999 Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 84:527-532
29. Colao A, Marzullo P, Lombardi G 2002 Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303-309
30. Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scamaltino F, Lombardi G 1999 Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months Clin Endocrinol (Oxf) 51:611-618
31. Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, Di Sarno A, Lombardi G 2000 Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab 85:3754-3761
32. Cozzi R, Barausse M, Sberna M, Lodrini A, Franzini A, Lasio G, Attanasio R 2000 Lanreotide 60 mg, a longer acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3:231-238
33. Ambrosio MR, Franceschetti P, Bondanelli M, Doga M, Maffei P, Baldelli R, Tamburrano G, Sicolo N, Giustina A, degli Uberti EC 2002 Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism 51:387-393
34. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB 2000 Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) 53:719-724
35. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL 1998 Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 83:3034-3040
36. Ferone D, Colao A, van der Lely A-J, Lamberts SWJ 2000 Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs 17:81-92
37. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 49:653-657
38. Laws ER, Vance ML, Thapar K 2000 Pituitary surgery for the management of acromegaly. Horm Res 53(Suppl 3):71-75
39. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
40. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R 2001 Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:717-726
41. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M 2003 Gamma-knife radiosurgery in acromegaly: a 4-year-follow-up study. J Clin Endocrinol Metab 88:3105-3112
42. Pedroncelli AM, Montini M, Gianola D, Pagani MD, Albani G, Dallabonzana D, Pagani G 2000 Octreotide LAR as first line therapy in acromegaly: preliminary results [OC16 Abstract]. Pituitary 3:20
43. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65-71
44. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
45. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G 2001 Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786
46. Van der Lely AJ, Harris AG, Lamberts SWJ 1992 The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 37:181-185
47. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM 2003 Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098
48. Sacks F for the Expert Group on HDL Cholesterol 2002 The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90: 139-143
49. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E 2000 LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 151:551-557
50. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
51. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W 2002 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104